Prof. Lewis C. Cantley
Professor of Cancer Biology in Medicine and is the Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine
Lewis Cantley has made significant advances in cancer research, stemming from his discovery of the signaling pathway phosphoinositide 3-kinase (PI3K) in 1984. His pioneering research has resulted in revolutionary treatments for cancer, diabetes and autoimmune diseases.
The author of over 400 original papers and more than 50 book chapters and review articles, Dr. Cantley is a fellow of the American Academy of Arts and Sciences and a member of the National Academy of Sciences. He graduated summa cum laude with a B.S. in chemistry from West Virginia Wesleyan College (1971) and obtained a Ph.D. in biophysical chemistry from Cornell University (1975).
He conducted postdoctoral research at Harvard University, where he was appointed assistant professor of biochemistry and molecular biology in 1978.
He became a professor of physiology at Tufts University in 1985, but returned to Harvard Medical School as professor of cell biology in 1992.
He became chief of Harvard’s new Division of Signal Transduction, and a founding member of its Department of Systems Biology in 2002.
In 2007, he was appointed director of the Beth Israel Deaconess Cancer Center. He joined the faculty of Weill Cornell Medical College and NewYork-Presbyterian Hospital in 2012
Title: PI 3-Kinase and Cancer Metabolism
Summary: Phosphoinositide 3-Kinase (PI3K) is activated by insulin and other growth factors to mediate cell growth. The PI3K enzyme encoded by the PIK3CA gene is one of the most frequently mutated oncogenes in human cancer.
This same enzyme mediates insulin responses in liver, muscle, fat and other tissues and drugs that inhibit this enzyme have the expected effect of raising serum glucose and insulin levels.
Data will be presented showing that dietary and pharmaceutical interventions that limit elevation of serum insulin improve responses to PI3K inhibitors in mouse models of cancer by preventing insulin-dependent activation of PI3K in tumors.
We have a number of membership categories available. Find out which membership suits you.
Due to COVID restrictions we have yet to confirm the dates for 57th Annual Conference.
Please check back here later in 2020 to check for updates.
IACR Public Engagement
Would you like to know more about how we involve patients in research, our fundraising, and lay seminars?
The Irish Association for Cancer Research will support a limited number of Educational Grants that will be made available to postgraduate PhD researchers who have been affected by the Covid-19 pandemic. We acknowledge that many of our members have been significantly impacted by the recent pandemic that may have affected their ability to continue and/or complete research projects.
for Cancer Research
9A Coolkill, Sandyford
Dublin 18, Ireland
+353 (0)295 8859
Irish Association for Cancer Research (IACR) is a registered charity on the Register of Charitable Organisations, Charities Regulator, 3 George's Dock, IFSC, Dublin 1, D01 X5X0, Ireland.
Registered Charity Number (RCN): 20030117.
©Design by LetterEleven